尿液纤溶酶原作为人类肾小球疾病进展的标志物
本研究为多中心队列研究,纳入CureGN队列中1010例经活检证实的肾小球疾病患者(局灶节段性肾小球硬化、膜性肾病和IgA肾病),评估基线尿纤溶酶(原)与终末期肾病(ESKD)的关联。调整后Log2uPlasminogen/cr每翻倍与ESKD风险显著相关(HR 1.31, 95%CI 1.22-1.40, P<0.001),且纤溶酶(原)模型预测性能优于UPCR模型。测量/预期纤溶酶(原)比值<0.8时HR 0.41(95%CI 0.22-0.77),>1.1时HR 2.42(95%CI 1.54-3.78)。
要点
- 尿纤溶酶(原)/肌酐每翻倍,ESKD风险增加31%(HR 1.31)。
- 纤溶酶(原)模型预测ESKD性能优于尿蛋白/肌酐比值模型。
- 测量/预期纤溶酶(原)比值<0.8或>1.1均与ESKD独立相关。
核心结论
- 尿纤溶酶(原)及测量/预期纤溶酶(原)比值与肾小球疾病患者进展至ESKD独立相关。
- 尿纤溶酶(原)可能成为预后决策的有用生物标志物及新疗法开发靶点。
研究设计与样本
- 多中心队列研究,纳入CureGN队列中1010例经活检证实的肾小球疾病患者(局灶节段性肾小球硬化、膜性肾病和IgA肾病)。
- 基线尿纤溶酶(原)采用新开发的电化学发光免疫分析法测量,传统临床和分析特征用于调整。
主要发现
- 调整后Log2uPlasminogen/cr每翻倍与ESKD显著相关(HR 1.31, 95%CI 1.22-1.40, P<0.001)。
- 包含Log2uPlasminogen/cr、Log2 UPCR或两者模型的预测性能比较显示纤溶酶(原)模型更优。
- 测量/预期尿纤溶酶(原)比值与ESKD独立相关:比值<0.8时HR 0.41(95%CI 0.22-0.77),比值>1.1时HR 2.42(95%CI 1.54-3.78)(参照比值0.8-1.1)。
临床怎么用
- 在蛋白尿和肾小球疾病患者中,尿纤溶酶(原)可用于风险分层,辅助及时干预决策。
- 测量/预期纤溶酶(原)比值可作为独立预测ESKD的指标。
局限性
- 单次纤溶酶(原)测定无法研究随时间的变化。
- 队列以白人患者为主且仅限三种肾小球疾病,限制了外部有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Glomerular disorders have a highly variable clinical course, and biomarkers that reflect the molecular mechanisms underlying their progression are needed. Based on our previous work identifying plasminogen as a direct cause of podocyte injury, we designed this study to test the association between urine plasmin(ogen) (ie, plasmin and its precursor plasminogen) and end-stage kidney disease (ESKD). STUDY DESIGN: Multicenter cohort study. SETTING & PARTICIPANTS: 1,010 patients enrolled in the CureGN Cohort with biopsy-proven glomerular disease (focal segmental glomerulosclerosis, membranous nephropathy, and immunoglobulin A nephropathy). PREDICTORS: The main predictor was urine plasmin(ogen) at baseline. Levels were measured by an electrochemiluminescent immunoassay developed de novo. Traditional clinical and analytical characteristics were used for adjustment. The ratio of urine plasmin(ogen)/expected plasmin(ogen) was evaluated as a predictor in a separate model. OUTCOME: Progression to ESKD. ANALYTICAL APPROACH: Cox regression was used to examine the association between urinary plasmin(ogen) and time to ESKD. Urinary markers were log2 transformed to approximate normal distribution and normalized to urinary creatinine (Log2uPlasminogen/cr, Log2 urinary protein/cr [UPCR]). Expected plasmin(ogen) was calculated by multiple linear regression. RESULTS: Adjusted Log2uPlasminogen/cr was significantly associated with ESKD (HR per doubling Log2 uPlasminogen/cr 1.31 [95% CI, 1.22-1.40], P<0.001). Comparison of the predictive performance of the models including Log2 uPlasminogen/cr, Log2 UPCR, or both markers showed the plasmin(ogen) model superiority. The ratio of measured/expected urine plasmin(ogen) was independently associated with ESKD: HR, 0.41 (95% CI, 0.22-0.77) if ratio<0.8 and HR 2.42 (95% CI, 1.54-3.78) if ratio>1.1 (compared with ratio between 0.8 and 1.1). LIMITATIONS: Single plasmin(ogen) determination does not allow for the study of changes over time. The use of a cohort of mostly white patients and the restriction to patients with 3 glomerular disorders limits the external validity of our analysis. CONCLUSIONS: Urinary plasmin(ogen) and the ratio of measured/expected plasmin(ogen) are independently associated with ESKD in a cohort of patients with glomerular disease. Taken together with our previous experimental findings, urinary plasmin(ogen) could be a useful biomarker in prognostic decision making and a target for the development of novel therapies in patients with proteinuria and glomerular disease. PLAIN-LANGUAGE SUMMARY: Glomerular diseases are an important cause of morbidity and mortality in patients of all ages. Knowing the individual risk of progression to dialysis or transplantation would help to plan the follow-up and treatment of these patients. Our work studies the usefulness of urinary plasminogen as a marker of progression in this context, since previous studies indicate that plasminogen may be involved in the mechanisms responsible for the progression of these disorders. Our work in a sample of 1,010 patients with glomerular disease demonstrates that urinary plasminogen (as well as the ratio of measured to expected plasminogen) is associated with the risk of progression to end-stage kidney disease. Urine plasminogen exhibited good performance and, if further validated, could enable risk stratification for timely interventions in patients with proteinuria and glomerular disease.
引用
- de Cos M, Mosoyan G, Chauhan K, et al. Urinary Plasminogen as a Marker of Disease Progression in Human Glomerular Disease. Am J Kidney Dis. 2024. PMID: 38452919. doi:10.1053/j.ajkd.2024.01.520
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。